INTRODUCTION {#s1}
============

Esophageal squamous cell carcinoma (ESCC) is the seventh most common cancer and the fifth most common cause of cancer-related death in the world \[[@R1]\]. Esophagectomy remains the mainstay of treatment for resectable disease. However, the prognosis for patients treated by surgery alone is poor. Recent developments in postoperative management, including chemotherapy and fractionized radiation therapy, have contributed to improvements in the surgical outcome \[[@R2]--[@R4]\]. Because chemotherapy is useful as adjuvant therapy before or after surgery for potentially resectable tumors, it has led to considerable interest in the identification of predictive biomarkers for selecting appropriate treatments for patients with ESCC.

Our previous study demonstrated that chromosomal amplification and hypoxia could induce the expression of EIF5A2, the eukaryotic translation initiation factor 5A2, and that it was important in epithelial-mesenchymal transition (EMT) and metastasis of ESCC \[[@R5]\]. Recently, the ablation or inhibition of EIF5A2 was also reported to enhance the chemosensitivity of HCC (hepatocellular carcinoma) cells to 5-fluorouracil (5-FU)/doxorubicin and breast cancer cells and bladder cancer cells to doxorubicin \[[@R6]--[@R9]\]. Despite these reports, the underlying mechanism of acquired chemosensitivity of silencing EIF5A2 is poorly defined. Because chemotherapy is becoming more widely used as adjuvant therapy for patients with ESCC, a better understanding of the mechanisms of chemoresistance of EIF5A2 is therefore critical for selecting treatments and the development of potential strategies to overcome chemoresistance.

In this study, we sought to explore the role of EIF5A2 in the chemoresistance of ESCC cells, and we tested the chemosensitivity in both EIF5A2 overexpressed cells and knock-down cells. In addition, EIF5A2 overexpression enhanced the stemness of ESCC cells and inhibited the apoptosis activated by chemotherapy treatment. Moreover, our results show that the EIF5A2 expression in resected ESCC specimens is correlated with a worse clinical outcome and response to adjuvant chemotherapy, suggesting an important clinical application of EIF5A2 in selecting appropriate chemo-treatments for patients with ESCC.

RESULTS {#s2}
=======

EIF5A2 increased the stemness of ESCC cells {#s2_1}
-------------------------------------------

Our previous study showed that EIF5A2 introduction could increase the tumorigenicity of ESCC cells *in vivo* and *in vitro* \[[@R5]\]. To determine whether *EIF5A2* introduction is sufficient to enhance the stemness of ESCC cells, the *eIF5A2* and vector stably transfected KYSE510 cells were established, and sphere assays were performed. The sphere-forming ability of 510-*eIF5A2* cells was significantly increased (*P* \< 0.05) compared to that of vector control cells (510-Vec) (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}), suggesting that EIF5A2 increased self-renewal ability.

![EIF5A2 overexpression increased the stemness of ESCC cells\
**A.** The protein level was determined in EIF5A2 overexpressed cells (510-*eIF5A2* and 410-*eIF5A2*) and vector control cells (510-Vec and 410-Vec) by western blotting assay. Tubulin was used as loading control. **B.** Representative pictures showing increased sphere-forming ability in 510-*eIF5A2* compared with 510-Vec cells. The results are summarized as the mean ± SEM of three independent assays. **C, D.** Relative expression of stemness-associated genes (*nanog*, *p75NTR* and *OCT-4*), surface antigens associated with ESCC cancer stem cells (*CD24* and *CD44*) and multi drug-resistant transporter gene (*ABCG2*) were compared by qRT-PCR between EIF5A2 overexpressed cells (510-*eIF5A2* and 410-*eIF5A2*) and corresponding vector control cells. **E, F.** The protein levels of nanog, p75NTR, CD24, CD44, ABCG2 increased in EIF5A2 overexpressed cells (510-*eIF5A2* and 410-*eIF5A2*) compared with vector control cells (510-Vec and 410-Vec). Actin was set as loading control.](oncotarget-06-26079-g001){#F1}

Then, we extended our analysis by examining the expression levels of stemness-associated genes by qRT-PCR on EIF5A2 overexpressed cells. The RNA levels of *nanog* \[[@R10]\], *p75NTR* \[[@R11]\], *OCT-4* \[[@R12]\], *CD24* \[[@R13]\] and *CD44* \[[@R14]\] increased in the range of 2.8-fold (*p75NTR*) up to 11-fold (*nanog*) in EIF5A2 overexpressed KYSE510 cells (510-*eIF5A2*) compared with vector control cells (*P* \< 0.01; Figure [1C](#F1){ref-type="fig"}). Similar results were also observed in EIF5A2 overexpressed KYSE410 cells (410-*eIF5A2*) (Figure [1A](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). Taken together, these findings revealed that EIF5A2 overexpression increased the stemness of ESCC cells. The RNA level of *ABCG2* (ATP-binding cassette, sub-family G, member 2) \[[@R15]\], a multiple drug-resistant transporter gene, also increased by 1.6-fold in 510-*eIF5A2* and 5.9-fold in 410-*eIF5A2* cells (*P* \< 0.01; Figure [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). The protein levels of nanog, p75NTR, CD24, CD44 and ABCG2 increased in varying degrees in EIF5A2 overexpressed cells (510-*eIF5A2* and 410-*eIF5A2*) compared with their respective vector control cells (Figure [1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}).

Chemoresistance induced by EIF5A2 overexpression {#s2_2}
------------------------------------------------

Because drug resistance is one of the characters of cancer stem cells and a multiple drug-resistant transporter gene increased in the EIF5A2 overexpressed cells, we next investigated whether EIF5A2 overexpression contributes to the chemoresistance of ESCC cells. For this purpose, XTT assays were used to evaluate the chemoresistance between EIF5A2 overexpressed KYSE510 cells (510-*eIF5A2*) and vector control cells (510-Vec). The 510-*eIF5A2* cells were more resistant to 5-FU than the vector cells (Figure [2A](#F2){ref-type="fig"}). The results demonstrated that 510-*eIF5A2* cells were more resistant to docetaxel and taxol than 510-Vec cells (Figure [2A](#F2){ref-type="fig"}). To rule out the possibility that the resistance of chemotherapy induced by EIF5A2 overexpression is specific to KYSE510 and its derivative cells, another ESCC cell line, KYSE410, was next studied. Similar results were observed in the 410-*eIF5A2* cells and 410-Vec cells (Figure [2B](#F2){ref-type="fig"}).

![EIF5A2 overexpression induced chemoresistance in ESCC cells\
**A.** 510-*eIF5A2* cells are more chemoresistant than 510-Vec cells at individual doses of 5-FU, docetaxel and taxol, as shown by XTT assay. \*, *P* \< 0.05; \*\*, *P* \< 0.01. **B.** 410-*eIF5A2* cells are more chemoresistant than 410-Vec cells at individual doses of 5-FU, docetaxel and taxol, as shown by XTT assay. \*, *P* \< 0.05; \*\*, *P* \< 0.01.](oncotarget-06-26079-g002){#F2}

Chemo-sensitivity increased by EIF5A2 silencing {#s2_3}
-----------------------------------------------

We next examined whether silencing EIF5A2 expression would increase the chemo-sensitivity by knocking down EIF5A2 expression in KYSE180 and EC109 cells. The ESCC cells were transduced with lentivirus containing shRNAs (sh1 and sh2) against *eIF5A2* (Figure [3A](#F3){ref-type="fig"}), and cytotoxicity assays were carried out. It was found that KYSE180 with reduced EIF5A2 expression were more sensitive to 5-FU, docetaxel and taxol than the vector control cells (Figure [3B, 3C](#F3){ref-type="fig"}). Similar results were observed in EC109 cells (Figure [3D, 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}).

![Knock-down of *eIF5A2* increased chemosensitivity\
**A.** Knock-down of *eIF5A2* by shRNAs (sh1 and sh2) compared with vector control was confirmed in KYSE180 cells by western blotting analysis. Tubulin was set as loading control. **B, C.** The *eIF5A2* knock-down cells (180-sh1 and 180-sh2) were significantly more sensitive than the vector cells at individual 5-FU (B), docetaxel and taxol (C) doses. \*, *P* \< 0.05; \*\*, *P* \< 0.01. **D.** Knock-down of *eIF5A2* was confirmed in EC109 cells by western blotting analysis. Tubulin was set as loading control. **E. F.** The *eIF5A2* knock-down EC109 cells were significantly more sensitive than the vector cells at individual 5-FU (E), docetaxel and taxol (F) doses. \*, *P* \< 0.05; \*\*, *P* \< 0.01.](oncotarget-06-26079-g003){#F3}

EIF5A2 conferred chemoresistance by inhibiting apoptosis in ESCC cells {#s2_4}
----------------------------------------------------------------------

We next elucidated whether EIF5A2 accounts for chemoresistance through inhibiting apoptosis. 510-*eIF5A2* cells and 510-Vec cells were treated with 5-FU, docetaxel and taxol, and *in situ* TUNEL assays were performed. As shown in Figure [4A](#F4){ref-type="fig"}, the number of apoptotic cells decreased in 510-*eIF5A2* cells compared with 510-Vec cells. Similar results were obtained in KYSE410 derived cells (Figure [4B](#F4){ref-type="fig"}). In contrast, KYSE180 transduced with shRNA suppressing *eIF5A2* (180-sh1) and vector control cells (180-Vec) were also treated with chemotherapeutic reagents, and the *in situ* TUNEL results also indicated an increased apoptotic response toward 5-FU, docetaxel and taxol in EIF5A2 knock-down cells compared with vector control cells (Figure [4C](#F4){ref-type="fig"}). Similar results were also obtained in EC109-derived cells (Figure [4D](#F4){ref-type="fig"}). These findings support that the preferential survival of EIF5A2 overexpressed cells after chemotherapy reagents was attributed to low rates of apoptosis. The activation of PARP and caspase-8, two typical characteristics of cell apoptosis, was also investigated by western blotting in EIF5A2 overexpressed cells and silenced cells. As shown in Figure [5A](#F5){ref-type="fig"}, the cleaved PARP and caspase-8 were decreased in the 510-*eIF5A2* cells compared with 510-Vec cells after treatment with 5-FU, docetaxel and taxol. In addition, overexpression of *eIF5A2* in KYSE410 significantly decreased the cleaved PARP in comparison with the vector control cells (Figure [5B](#F5){ref-type="fig"}). As shown in Figure [5C](#F5){ref-type="fig"}, EIF5A2 knock-down resulted in an increase of PARP and caspase-8 activation in KYSE180 cells after treatment with 5-FU, docetaxel and taxol. Additionally, EIF5A2 knock-down resulted in an activation of PARP in EC109 cells treated with 5-FU, docetaxel and taxol (Figure [5D](#F5){ref-type="fig"}).

![*in situ* cell death assay showed the effect of EIF5A2 on chemoresistance of ESCC cells\
After treatment with 5-FU, docetaxel and taxol for 48 h, in situ TUNEL assays were performed on cells. Representative images of TUNEL assay are shown. The apoptotic cells were stained a brown color, and the nuclei were counterstained with hematoxylin. EIF5A2 overexpressed 510 **A.** and 410 **B.** cells showed fewer apoptotic cells than their respective vector controls, whereas *eIF5A2* knock-down increased apoptotic cells in 180 **C.** and EC109 cells **D.** compared with their respective vector controls (original magnification: 20×). Summary of apoptotic cells ratio (/Vec) was shown (right). \*, *P* \< 0.05; \*\*, *P* \< 0.01.](oncotarget-06-26079-g004){#F4}

![EIF5A2 conferred chemoresistance by inhibiting apoptosis\
**A.** Cleaved PARP and Caspase-8 were found to be inhibited in *EIF5A2* overexpressed 510 cells in response to 5-FU (50 μM), docetaxel (0.02 μM) and taxol (0.001 μM) when analyzed by western blotting analysis. **B.** Activation of PARP was inhibited in 410-*eIF5A2* cells when treated with 5-FU (5 μM), docetaxol (0.01 μM) and taxol (0.0075 μM) compared with 410-Vec cells. **C.** Cleaved PARP and Caspase-8 were increased in *eIF5A2* knock-down 180 cells treated with 5-FU (60 μM), docetaxel (0.01 μM) and taxol (0.003 μM) compared with 180-Vec cells. **D.** Activation of PARP was increased in EC109-sh cells when treated with 5-FU (50 μM), docetaxel (0.015 μM) and taxol (0.007 μM) compared with vector control cells. Tubulin or actin was set as loading control.](oncotarget-06-26079-g005){#F5}

EIF5A2 overexpression correlated with a poorer outcome of chemotherapy {#s2_5}
----------------------------------------------------------------------

To further explore the role of EIF5A2 in chemoresistance in clinical samples, we evaluated the expression of EIF5A2 by IHC in patients who underwent taxane-based chemotherapy after esophagectomy. Positive staining of EIF5A2 was detected in 40 of 89 (44.94%) tumor tissues and negative staining was detected in 49 of 89 (55.06%) tumor cases (Figure [6A](#F6){ref-type="fig"}). The association study demonstrated that EIF5A2 expression was not significantly associated with gender, age, differentiation status or T status, but it was significantly associated with N status (*P* = 0.011) (Table [1](#T1){ref-type="table"}). The Kaplan-Meier survival analysis revealed that EIF5A2 expression was correlated with poorer overall survival (OS) in patients who underwent postoperative taxane-based chemotherapy (log-rank test, *P* = 0.047) (Figure [6B](#F6){ref-type="fig"}). The mean OS time of the EIF5A2(−) and EIF5A2(+) groups were 62.08 months (95% CI: 52.03--72.14) and 47.77 months (95% CI: 35.97--59.58), respectively.

![EIF5A2 expression correlated with a poorer outcome of chemotherapy\
**A.** The representative images of EIF5A2 negative and positive expression in ESCC tissues (original magnification: 20×). **B.** Kaplan-Meier analysis indicated that the overall survival rate of patients with ESCC who received postoperative taxane-based chemotherapy was significantly decreased in the EIF5A2(+) group compared with the EIF5A2(−) group (*P* = 0.047).](oncotarget-06-26079-g006){#F6}

###### Correlation between EIF5A2 expression and clinicopathological features of primary ESCC

  Clinicopathological features   All cases   EIF5A2 expression   *P* value    
  ------------------------------ ----------- ------------------- ------------ -------
  **Gender**                                                                  0.924
   female                        13          7 (53.8%)           6 (46.2%)    
   male                          76          42 (55.3%)          34 (44.7%)   
  **Age**                                                                     0.221
   \< 57 year                    53          32 (60.4%)          21 (39.6%)   
   ≥ 57 year                     36          17 (47.2%)          19 (52.8%)   
  **Differentiation**                                                         0.184
   1--2                          62          37 (59.7%)          25 (40.3%)   
   3                             27          12 (44.4%)          15 (55.6%)   
  **T status**                                                                0.119
   T1-T2                         15          11 (73.3%)          4 (26.7%)    
   T3-T4                         74          38 (51.4%)          36 (48.6%)   
  **N status**                                                                0.011
   N0                            20          16 (80.0%)          4 (20.0%)    
   N1                            69          33 (47.8%)          36 (52.2%)   

Note: The Pearson Chi-Square test was used as statistical analysis. Significant difference was defined when *P* \< 0.05.

DISCUSSION {#s3}
==========

ESCC is one of the most lethal malignancies of the digestive tract in East Asian countries. Often, when many cases are initially diagnosed, the malignancy is already in an advanced stage. Multimodal therapies are necessary to prolong the survival of patients with ESCC. Adjuvant chemotherapy and neo-adjuvant chemotherapy have become the first-line therapy for patients with advanced ESCC \[[@R4]\]. However, the effectiveness of chemotherapy is often limited by drug resistance of the patients. Therefore, it is very important to screen predictive biomarkers for chemosensitivity to select appropriate regimens for patients with ESCC.

Overexpression of EIF5A2 has been detected in many solid tumors, including ovarian cancer \[[@R16]\], hepatocellular carcinoma \[[@R17], [@R18]\], non-small cell lung cancer \[[@R19]\], bladder cancer \[[@R20]\], melanoma \[[@R21]\], colorectal cancer \[[@R22]\], pancreatic adenocarcinoma \[[@R23]\] and ESCC \[[@R5]\]. It was also reported that EIF5A2 could promote tumor metastasis and angiogenesis in ESCC and hepatocellular carcinoma \[[@R5], [@R6], [@R18]\]. Our previous studies found that EMT was involved in the above processes \[[@R5], [@R18]\]. Because EMT is not only a process to acquire metastasis but also a complicated reprogramming process through which differentiated epithelial cells reverse to an undifferentiated state by acquiring stem cell-like function \[[@R24]\], we tested whether forced expression of EIF5A2 could endow the cells with stem cell properties. Our results indicated that EIF5A2 overexpression enhanced the stemness of the 510-*eIF5A2* cells and induced multiple cancer stem cell markers.

Cancer stem cells are supposed to be responsible for not only tumor initiation and maintenance but also resistance to chemotherapy, radiotherapy and early recurrence. We previously reported that shRNAs suppressing *eIF5A2* combined with chemotherapeutic reagent effectively reduced the volume and weight of xenografts in nude mice \[[@R5]\]. Additionally, some *in vitro* studies reported that knock-down or inhibition of EIF5A2 enhanced the chemosensitivity of HCC cells to 5-FU/doxorubicin and breast cancer cells and bladder cancer cells to doxorubicin \[[@R6]--[@R9]\]. Because adjuvant therapy has been increasingly used in the treatment of advanced ESCC, we tested whether EIF5A2 induced chemoresistance of ESCC cells. The overexpression of *eIF5A2* in the ESCC cells (KYSE510 and KYSE410) led to increased chemoresistance to 5-FU, docetaxel and taxol; whereas shRNA-mediated silencing of *eIF5A2* in the ESCC cells (KYSE180 and EC109) increased chemosensitivity towards these chemotherapeutic agents.

Cancer stem cell chemoresistance is explained by slow cycling, efflux of drugs by ATP binding cassette transporters and upregulation of anti-apoptosis \[[@R25], [@R26]\]. Our study found that the RNA and protein levels of *ABCG2* were increased in EIF5A2 overexpressed cells. ABCG2 is an important member of the ABC transporter superfamily that has been suggested to be involved in multidrug resistance in cancer \[[@R27]\]. It has a diverse range of substrates, including doxorubicin, imatinib, and mitoxantrone \[[@R28]\]. This result is consistent with the previous findings that silencing or inhibition of EIF5A2 led to sensitization of some cancer cells toward doxorubicin \[[@R7]--[@R9]\].

5-FU is widely used in cancer chemotherapy. It inhibits thymidylate synthase, an essential enzyme for the *de novo* synthesis of thymidylate and subsequently DNA synthesis. This results in imbalance of dTTP/dUTP and DNA damage. Both the imbalance and DNA damage lead to apoptosis \[[@R29]\]. It was also reported that silencing of endogenous EIF5A2 increased tumor perfusion by remodeling tumor vessels, thus increased the chemosensitivity of HCC cells to 5-FU *in vivo* \[[@R6]\]. In this study, western blotting assay demonstrated that overexpression of EIF5A2 reduced the activation of PARP and caspase-8 after treatment with chemotherapeutics; in contrast, knock-down of EIF5A2 increased the PARP and caspase-8 activation in comparison with the vector control cells. These findings support the role of anti-apoptosis in the gain and manifestation of chemoresistance conferred by EIF5A2 in ESCC cells.

Long-term survival of patients with ESCC is poor due to high rates of therapeutic failure and tumor relapse. Discovering reliable chemosensitivity markers that could accurately predict clinical outcome is beneficial. In our study, the Kaplan-Meier analysis indicated that EIF5A2 expression was associated with a poorer survival in patients with ESCC who underwent taxane-based chemotherapy after esophagectomy. Based on our results, we believe that inhibition of EIF5A2 could be a highly effective strategy in overcoming 5-FU or taxane-based chemoresistance in a clinical setting. N1-guanyl-1, 7-diaminoheptane (GC7), which inhibits EIF5A2 activation \[[@R8]\], could be considered as a combination therapy to enhance chemosensitivity in patients with ESCC.

MATERIALS AND METHODS {#s4}
=====================

Patients and tissue samples {#s4_1}
---------------------------

Between December 2004 and August 2009, a retrospective cohort of 89 patients with ESCC who underwent esophagectomy with adjuvant chemotherapy at Sun Yat-sen University Cancer Center was enrolled in this study. The patients were diagnosed with primary ESCC, and none of them had received preoperative chemotherapy, preoperative radiotherapy, or concurrent chemoradiotherapy. Staging was uniformly defined using the criteria set forth by the 6^th^ edition of American Joint Committee on Cancer Guidelines. Of the 89 patients who received taxane-based chemotherapy, 62 (69.7%) underwent taxol-based regimens and 27 (30.3%) underwent docetaxel-based regimens. The age of the patients ranged from 35 to 72 years at the time of surgery (median age: 55 years). The median follow-up time was 60 months (inverted Kaplan-Meier analysis) \[[@R30]\]. Tissue samples used in the study were approved by the Committees for Ethical Review of Research Involving Human Subjects in Sun Yat-sen University Cancer Center.

Cell lines {#s4_2}
----------

ESCC cell lines KYSE510, KYSE180, and KYSE410 were obtained from DSMZ, the German Resource Center for Biological material \[[@R31]\]. EC109 was kindly provided by Professor G. Srivastava \[[@R32]\]. Cells were maintained in DMEM medium (Gibco BRL, NY) supplemented with 10% fetal bovine serum (ExCell, Shanghai, China). 293FT cells were purchased from Invitrogen (Carlsbad, CA).

Virus production and stable cell lines established {#s4_3}
--------------------------------------------------

The plenti-*eIF5A2* construct was purchased from GeneCopoeia (Guangzhou, China). The constructs containing shRNAs suppressing *eIF5A2* were from Sigma-Aldrich company (Shanghai, China). The lentiviruses were packaged in 293FT cells according to the manufacturer\'s protocol (Invitrogen, CA). The stable cell lines (overexpressed or knock-down) were established after cells were transduced with lentiviruses (plenti-*eIF5A2* or shRNAs) and selected with puromycin. The concentration of puromycin for the cell lines selection was listed as: KYSE510 (1.2 μg/ml), KYSE410 (0.6 μg/ml), KYSE180 (0.5 μg/ml) and EC109 (0.6 μg/ml).

Sphere assay {#s4_4}
------------

510-*eIF5A2* and vector control cells were seeded into 24-well polyHEMA-coated plates (Sigma-Aldrich, St Louis, MO) and cultured for 2 weeks in DMEM/F12 medium supplemented with 4 μg/mL insulin (Bioind, Kibbutz Beit haemek, Israel), B27 (Gibco, Grand island, NY), 20 ng/mL EGF (PeproTech, Rocky Hill, NJ) and 10 ng/mL basic FGF (PeproTech). Cells were replenished with fresh medium every second day \[[@R33]\]. The spheres in the suspension culture were counted under microscope (Olympus IX71) \[[@R34]\].

Quantitative real-time PCR (qRT-PCR) {#s4_5}
------------------------------------

Total RNA from cells was extracted using Trizol (Invitrogen, CA) according to the manufacturer\'s instructions. Reverse transcription was performed using the SuperScript reverse transcriptase (Invitrogen, CA). The cDNA was subjected to qRT-PCR using the SYBR Green reagent (Roche, Mannheim, Germany) and an ABI 7900HT Fast Real-time PCR system (Applied Biosystems). 18S rRNA was used as internal control. The assays were performed in triplicate, and values were normalized using the internal control. PCR products were subjected to dissociation curve analysis to exclude amplification of nonspecific products. Quantitative data were analyzed using the ΔCt method. The primer sequences are listed in the [Supplementary Data](#SD1){ref-type="supplementary-material"}.

Western blotting {#s4_6}
----------------

Cells were lysed with RIPA buffer (Cell signaling technology, Danvers, MA), the proteins were fractionated by SDS-PAGE and western blotting was performed. The blots were incubated with diluted primary antibodies overnight at 4°C. Then, blots were exposed to the appropriate peroxidase-conjugated secondary antibodies (Cell Signaling Technology, MA) at 1:3000 for 2 h at room temperature. Finally blots were developed with Luminata Crescendo western HRP substrate (Millipore, MA). The following antibodies were used: EIF5A2 (1:1000) (Wolwo, Shanghai, China), Casepase-8 (1:1000), PARP (1:1000), CD44 (1:500), nanog (1:500) and p75NTR (1:500) (Cell Signaling Technology, MA), ABCG2 (1:500), CD24 (1:500), β-tubulin (1:1000) and actin (1:1000) (Santa Cruz Biotechnology, TX).

Cytotoxicity assay {#s4_7}
------------------

The drugs used in the study were: 5-FU (SunRise Ltd., Shanghai, China), docetaxel (Aventis Pharma S.A., Bridgewater, NJ) and taxol (Wellso Pharma, Beijing, China). Chemotherapy-induced cytotoxicity was determined using an XTT assay (CCK-8, Dojindo, Kyushu, Japan). Cells were plated in 96-well plates at the appropriate density. Twenty-four hours later, cells were treated with 2-fold diluted concentrations of drugs for another 70 hours at 37°C. Then the XTT assay was performed and assayed at OD450 according to the manufacturer\'s instructions. Three independent assays were performed.

*In situ* cell death detection assay {#s4_8}
------------------------------------

Apoptotic cells were detected using an *in situ* Cell Death Detection Kit (Roche Applied Science, IN) according to the protocol. Cells were plated on the cover slides and treated with different chemotherapy regents. Forty-eight hours later, cells were washed with PBS and fixed in 4% paraformaldehyde. After blocking and incubation in permeabilisation buffer, apoptotic cells were determined by the terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay. Signal was converted by adding Concerter-POD and analyzed under light microscope.

Immunohistochemistry (IHC) {#s4_9}
--------------------------

IHC was performed using the standard streptavidin-biotin-peroxidase complex method. Briefly, the tissue sections were deparaffinized and subjected to antigen retrieval in EDTA antigen retrieval buffer (ZSGB-BIO, Beijing, China). Then the sections were incubated with the diluted primary antibody EIF5A2 (1:50) (Wolwo, Shanghai, China) overnight at 4°C. After incubation with horseradish peroxidase-linked secondary antibody (Real Envision Detection Kit, Gene Tech, Shanghai, China) for 30 min, the sections were counterstained with Mayer\'s hematoxylin. Expression of EIF5A2 was scored as absent (total absence of staining), very weak (faint staining in \< 25% of tumor cells), moderate (moderate staining in ≥ 25% to \< 75%, or strong staining in \< 25% of tumor cells), and strong (moderate staining in ≥ 75% or strong staining in ≥ 25% of tumor cells). In the present study, absent/very weak staining was defined as negative staining and moderate/strong staining as positive staining.

Statistical analysis {#s4_10}
--------------------

Statistical calculations were carried out with the SPSS 16.0 software package (SPSS, Inc., Chicago, IL). Survival curves were generated according to the Kaplan-Meier method and log-rank tests. All data were expressed as the means ± SEM. The results were considered statistically significant when *P* \< 0.05.
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